Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» February 2013
February 2013
BIO, PhRMA Blast FDA Draft Guidance on E-Subs for Trial Site Data
BIO, PhRMA Blast FDA Draft Guidance on E-Subs for Trial Site Data
Outsourcing Pharma
PhRMA
FDA
BIO
clinical trials
Lundbeck given EU nod for alcohol dependence drug
Lundbeck given EU nod for alcohol dependence drug
Reuters
Lundbeck
Europe
alcoholism
Selincro
The Pharma Influence On Budding Medical Trainees
The Pharma Influence On Budding Medical Trainees
Pharmalot
physicians
Fresenius, B. Braun IV Fluids Tied to More Deaths, Study Finds
Fresenius, B. Braun IV Fluids Tied to More Deaths, Study Finds
Bloomberg
IV fluids
Fresenius
B. Braun
Menopause Drugs from Depomed, Hisamitsu Offer Benefits
Menopause Drugs from Depomed, Hisamitsu Offer Benefits
Bloomberg
Depomed
Hisamitsu
menopause
hot flashes
gabapentin
paroxetine mesylate
Incyte's Jakafi Is Likely A $1 Billion Drug
Incyte's Jakafi Is Likely A $1 Billion Drug
Seeking Alpha
Jakafi
Incyte
myelofibrosis
AVEO to meet with FDA about tivozanib
AVEO to meet with FDA about tivozanib
Bizjournals.com
FDA
Aveo
tivozanib
kidney cancer
3 Bio-Pharmaceuticals You Can't Ignore
3 Bio-Pharmaceuticals You Can't Ignore
Motley Fool
Amarin
Vivus
Arena Pharmaceuticals
A Drug That's Ready to Lose
A Drug That's Ready to Lose
Motley Fool
Belviq
Arena Pharmaceuticals
Vivus
Eisai
It's Now Time For Vivus Investors To Watch Arena Numbers
It's Now Time For Vivus Investors To Watch Arena Numbers
Seeking Alpha
Vivus
Arena
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »